Related Experiment Video
Updated: Oct 8, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
A molecular target of vascular calcification in chronic kidney disease
Insights
SIRT6 protein prevents vascular calcification in chronic kidney disease (CKD) by inhibiting the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). This research identifies SIRT6 as a potential therapeutic target for treating vascular calcification in CKD patients.
Area of Science:
- Nephrology
- Cardiovascular Biology
- Molecular Medicine
Background:
- Vascular calcification (VC) is a significant complication in chronic kidney disease (CKD), leading to increased cardiovascular morbidity and mortality, especially in end-stage kidney disease (ESKD) patients on dialysis.
- The precise molecular mechanisms underlying VC in CKD remain incompletely understood, necessitating further investigation into potential therapeutic targets.
Purpose of the Study:
- To elucidate the molecular mechanism by which SIRT6 exerts a protective role against vascular calcification (VC) in the context of chronic kidney disease (CKD).
- To investigate the potential of targeting SIRT6 as a therapeutic strategy for managing VC in CKD patients.
Main Methods:
- Employed in vitro and animal models specifically designed to mimic conditions of chronic kidney disease (CKD).
- Investigated the interaction between SIRT6 and the transcription factor Runx2 (runt-related transcription factor 2).
- Utilized techniques to assess protein deacetylation, nuclear export, and proteasomal degradation pathways.
Main Results:
- Demonstrated that SIRT6 effectively prevents vascular calcification (VC) by suppressing the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs).
- Mechanistically, SIRT6 was shown to bind and deacetylate Runx2, a critical transcription factor for osteogenic differentiation.
- This SIRT6-mediated deacetylation promotes the nuclear export and subsequent proteasomal degradation of Runx2, thereby inhibiting VC.
Conclusions:
- The study identifies a novel molecular pathway in the pathogenesis of vascular calcification (VC) relevant to chronic kidney disease (CKD).
- SIRT6 plays a crucial protective role in preventing VC by regulating VSMC osteogenic transdifferentiation via the Runx2 pathway.
- These findings strongly support the investigation of SIRT6 as a potential therapeutic target for mitigating vascular calcification in CKD.
Abstract:
Vascular calcification (VC) causes cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD), particularly those with end-stage kidney disease (ESKD) on maintenance dialysis treatment. Although many mechanisms have been proposed, their detailed effects remain incompletely understood. In this issue of the JCI, Li et al. examined the molecular mechanism of the protective role of SIRT6 in VC in patients with CKD. Using in vitro and animal models of CKD, the authors demonstrated that SIRT6 prevents VC by suppressing the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). Mechanistically, SIRT6 bound and deacetylated the runt-related transcription factor 2 (Runx2), a key transcription factor for osteogenic differentiation, promoting its nuclear export for proteasome degradation. These studies provide a pathway in the pathogenesis of VC and justify investigating SIRT6 as a potential target in CKD.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease IV: Nursing Management
Skeleton and Calcium Homeostasis

